This finding mirrors the data of our collaborators from Cardiff University [unpub obs] where they have shown that small molecule inhibitors of p38MAPK can preferentially sensitize human fibroblasts with abrogated p53 (RNAi knock-down) to DNA damaging agents, suggesting a similar mechanism could also be functional in cancer cells. Here, TP53 is linked to cancer.